UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Molecular effects of inhaled glucocorticoid therapy in asthma

Author
Peter J Barnes, DM, DSc, FRCP, FRS
Section Editors
Bruce S Bochner, MD
Robert A Wood, MD
Deputy Editor
Helen Hollingsworth, MD

INTRODUCTION

Inhaled glucocorticoids (ie, glucocorticosteroids, corticosteroids, steroids) suppress airway inflammation by activating anti-inflammatory genes, switching off inflammatory gene expression, and inhibiting inflammatory cells. In addition, they enhance beta 2 adrenergic signaling by increasing beta 2-receptor expression and function. The net effect is control of the symptoms and signs of asthma in most patients.

The molecular effects of inhaled glucocorticoids in asthmatic airways are discussed in this topic review. In addition, the molecular determinants of glucocorticoid sensitivity are reviewed. The pharmacology of glucocorticoids, the role of inhaled glucocorticoids in the management of asthma, and the potential adverse effects of inhaled glucocorticoids are presented separately. (See "Pharmacologic use of glucocorticoids" and "Determinants of glucocorticoid dosing" and "An overview of asthma management" and "Asthma in children younger than 12 years: Initiating therapy and monitoring control" and "Mechanisms and clinical implications of glucocorticoid resistance in asthma" and "Major side effects of inhaled glucocorticoids".)

SUPPRESSION OF INFLAMMATION

Discoveries related to gene transcription have improved our understanding of the mechanisms by which inhaled glucocorticoids suppress airway inflammation [1,2]. These mechanisms include anti-inflammatory gene activation and switching off inflammatory gene expression, which alter the expression of inflammatory and anti-inflammatory enzymes, receptors, cytokines, adhesion molecules, and chemokines. The net effect is decreased inflammatory cell recruitment, survival, and accumulation.

Anti-inflammatory gene activation — There are two types of glucocorticoid receptors (GR), GR alpha and GR beta. Glucocorticoid action is facilitated by GR alpha, but potentially inhibited by GR beta.

GR alpha – Glucocorticoids passively diffuse across the cell membrane and bind to GR alpha in the cytoplasm [1]. The glucocorticoid/GR alpha complex (ie, activated GR) rapidly translocates into the nucleus. There, the activated GR form dimers, which bind to glucocorticoid response elements (GREs) within the promoter of glucocorticoid-responsive genes. There are positive and negative GREs.

Interaction with positive GREs stimulates gene transcription. Such genes usually encode anti-inflammatory proteins [3]. As an example, glucocorticoids stimulate expression of secretory leukoprotease inhibitor and mitogen-activated protein kinase phosphatase-1 (MKP-1), which inhibit mitogen-activated protein (MAP) kinase pathways (figure 1) [4]. Interaction with positive GREs appears to account for most of the side effects of glucocorticoids [5]. As an example, binding the GR to the promoter site on the osteocalcin gene interferes with its transcription, resulting in reduced expression and reduction in bone synthesis.

Interaction with negative GREs suppresses gene transcription, but there are only a few examples of reduced expression of inflammatory genes through interaction with negative GREs, indicating that other molecular mechanisms are involved in the suppression of inflammation.

     

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Wed Aug 05 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med 2005; 353:1711.
  2. Barnes PJ. Glucocorticosteroids: current and future directions. Br J Pharmacol 2011; 163:29.
  3. Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J 2006; 27:413.
  4. Clark AR. MAP kinase phosphatase 1: a novel mediator of biological effects of glucocorticoids? J Endocrinol 2003; 178:5.
  5. Dostert A, Heinzel T. Negative glucocorticoid receptor response elements and their role in glucocorticoid action. Curr Pharm Des 2004; 10:2807.
  6. Lewis-Tuffin LJ, Cidlowski JA. The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance. Ann N Y Acad Sci 2006; 1069:1.
  7. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005; 25:552.
  8. Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 2000; 20:6891.
  9. Ito K, Yamamura S, Essilfie-Quaye S, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med 2006; 203:7.
  10. Barnes PJ. Role of GATA-3 in allergic diseases. Curr Mol Med 2008; 8:330.
  11. Maneechotesuwan K, Yao X, Ito K, et al. Suppression of GATA-3 nuclear import and phosphorylation: a novel mechanism of corticosteroid action in allergic disease. PLoS Med 2009; 6:e1000076.
  12. Bergmann MW, Staples KJ, Smith SJ, et al. Glucocorticoid inhibition of granulocyte macrophage-colony-stimulating factor from T cells is independent of control by nuclear factor-kappaB and conserved lymphokine element 0. Am J Respir Cell Mol Biol 2004; 30:555.
  13. Brook M, Tchen CR, Santalucia T, et al. Posttranslational regulation of tristetraprolin subcellular localization and protein stability by p38 mitogen-activated protein kinase and extracellular signal-regulated kinase pathways. Mol Cell Biol 2006; 26:2408.
  14. Hart L, Lim S, Adcock I, et al. Effects of inhaled corticosteroid therapy on expression and DNA-binding activity of nuclear factor kappaB in asthma. Am J Respir Crit Care Med 2000; 161:224.
  15. Gibson PG, Saltos N, Fakes K. Acute anti-inflammatory effects of inhaled budesonide in asthma: a randomized controlled trial. Am J Respir Crit Care Med 2001; 163:32.
  16. Ketchell RI, Jensen MW, Lumley P, et al. Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5'-monophosphate in mild asthma. J Allergy Clin Immunol 2002; 110:603.
  17. Juniper EF, Kline PA, Vanzieleghem MA, et al. Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. Eur Respir J 1990; 3:1122.
  18. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002; 19:182.
  19. Nino G, Hu A, Grunstein JS, Grunstein MM. Mechanism of glucocorticoid protection of airway smooth muscle from proasthmatic effects of long-acting beta2-adrenoceptor agonist exposure. J Allergy Clin Immunol 2010; 125:1020.
  20. Mak JC, Nishikawa M, Barnes PJ. Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung. Am J Physiol 1995; 268:L41.
  21. Baraniuk JN, Ali M, Brody D, et al. Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med 1997; 155:704.
  22. Mak JC, Nishikawa M, Shirasaki H, et al. Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo. J Clin Invest 1995; 96:99.
  23. Mak JC, Chuang TT, Harris CA, Barnes PJ. Increased expression of G protein-coupled receptor kinases in cystic fibrosis lung. Eur J Pharmacol 2002; 436:165.
  24. Roth M, Johnson PR, Rüdiger JJ, et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002; 360:1293.
  25. Usmani OS, Ito K, Maneechotesuwan K, et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med 2005; 172:704.
  26. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009; 373:1905.
  27. Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2013; 131:636.